[{"id":"9e89006d-b52b-45d1-b2b6-670282331015","acronym":"","url":"https://clinicaltrials.gov/study/NCT01089101","created_at":"2021-01-17T17:15:45.070Z","updated_at":"2024-07-02T16:35:07.463Z","phase":"Phase 1/2","brief_title":"Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma","source_id_and_acronym":"NCT01089101","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • KIAA1549-BRAF fusion • BRAF fusion","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KIAA1549-BRAF fusion • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 04/19/2010","start_date":" 04/19/2010","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-25"},{"id":"3d9a5b08-ffd8-40b1-8c6f-4f95a249b8b2","acronym":"TRAM-01","url":"https://clinicaltrials.gov/study/NCT03363217","created_at":"2021-01-18T16:35:58.992Z","updated_at":"2024-07-02T16:35:28.095Z","phase":"Phase 2","brief_title":"Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.","source_id_and_acronym":"NCT03363217 - TRAM-01","lead_sponsor":"St. Justine's Hospital","biomarkers":" BRAF • NF1 • KIAA1549","pipe":" | ","alterations":" KIAA1549-BRAF fusion • BRAF fusion","tags":["BRAF • NF1 • KIAA1549"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIAA1549-BRAF fusion • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 08/16/2018","start_date":" 08/16/2018","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2023-11-27"},{"id":"909396a0-980d-4b31-bbf9-a9299740d296","acronym":"","url":"https://clinicaltrials.gov/study/NCT01386450","created_at":"2021-01-18T05:41:18.193Z","updated_at":"2024-07-02T16:37:15.606Z","phase":"Phase 2","brief_title":"AZD6244 in Children With Low-Grade Gliomas","source_id_and_acronym":"NCT01386450","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • KIAA1549","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KIAA1549-BRAF fusion • BRAF fusion","tags":["BRAF • KIAA1549"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KIAA1549-BRAF fusion • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 10/01/2016","primary_completion_date":" 10/01/2016","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2017-12-12"}]